Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 101 - 120 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Takeaways from our UCD Expert Call with Dr. Brendan Lee
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
17 Doc Calls Across 9 Therapeutic Areas Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Join our Mar. 30 Call to Calculate ACER-001''s Market Opportunity in UCD
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2019 Financial Results Reported; EDSIVO Residual Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
18 Doc Calls Across 8 Therapeutic Areas Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 19 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Which Orphan Companies to See and Why at Our 32nd Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 8 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 Part B Bioequivalence Study Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Dropping Coverage Due to Realignment of Analyst Resources
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 10 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 11 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 12 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y